tucatinib + eribulin + trastuzumab

This is a triple combination regimen consisting of **tucatinib** (a selective HER2-directed tyrosine kinase inhibitor), **eribulin** (a microtubule dynamics inhibitor), and **trastuzumab** (a monoclonal antibody targeting human epidermal growth factor receptor 2, HER2). The combination is being evaluated primarily for **previously treated, unresectable, locally advanced or metastatic HER2-positive breast cancer**. Tucatinib inhibits HER2 signaling, eribulin blocks microtubule polymerization, and trastuzumab interferes with HER2-mediated cellular proliferation, together providing a multidimensional targeted approach against HER2-positive malignancies[1][2][3][5][8].